A Phase 3 interventional study of Eltrombopag oral tablets in Idiopathic Thrombocytopenic Purpura and Purpura, Thrombocytopenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-09-17.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 31st largest by enrollment, is the only one that started in 2008, is one of 9 in phase 3, and was the 7th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Renata PLC · Sites in Bangladesh
Ages 18–70
Nahda University · Sites in Egypt
Ages 18–65
Novartis Pharmaceuticals
Ages 5–17
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 36 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
11 studies in Purpura, Thrombocytopenic, Idiopathic by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 11 finished, 6 (55%) have results posted.
Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by GlaxoSmithKline, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2008, is one of 4 in phase 3, and was the 7th registered.
GlaxoSmithKline’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2005.
1 of the studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189910Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 11 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An open-label, dose-adjustment extension study to evaluate the safety and efficacy of eltrombopag for treatment of subjects with ITP who have previously been enrolled in the eltrombopag trial TRA108109 (NCT00540423).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eltrombopag oral tablets once daily
Drug: Eltrombopag oral tablets
Eltrombopag oral tablets once daily
Also known as: SB-497115-GR oral tablets
Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category
An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medical product, whether or not related to the product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or its prolongation, results in disability/incapacity, is a congenital anomaly/birth defect, or is another event considered serious. A drug-related AE is any AE that was judged to have a relationship with the study medication by the investigator. The severity of an AE is based on the investigator's clinical judgment.
Time frame: From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)
Percentage of Participants Achieving a Platelet Count Greater Than or Equal to 50 Giga Unit (10^9) Per Liter (Gi/L) and Less Than or Equal to 400 Gi/L
Platelet counts were measured by blood draw.
Time frame: Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, and 136; and last visit/early withdrawal visit (up to Day 982)
Median Platelet Counts
Platelet counts were measured by blood draw.
Time frame: Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, and 136; and last visit/early withdrawal visit (up to Day 982)
Percentage of Participants With a Given Maximum Number of Weeks of Continuous Platelet Count Evaluation Greater Than or Equal to 50 Gi/L and Greater Than or Equal to Twice the Baseline Count Categorized by Weeks on Study Medication (Med.)
Maximum continuous week (MCW) is measured as the longest period (weeks) for which a participant continuously maintained platelet counts greater than or equal to 50 Gi/L and greater than or equal to twice the Baseline count.
Time frame: From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)
Median Number of Maximum Continuous Weeks of Maintaining Platelet Counts Greater Than or Equal to 50 Gi/L and Greater Than or Equal to Twice the Baseline Count at Three-Month Intervals
Maximum continuous week is measured as the longest period (weeks) for which a participant continuously maintained platelet counts greater than or equal to 50 Gi/L and greater than or equal to twice the Baseline count.
Time frame: 3, 6, 9, 12, 15, 18, 21, 24, 27, and 30 months (13, 26, 39, 52, 65, 78, 91, 104, 117, and 130 weeks)
Percentage of Participants Experiencing Any Bleeding Episode After Dosing With Study Medication
Any bleeding(s) with an onset on or after the start date of study medication was recorded as a bleeding episode(s).
Time frame: Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, and 136; and last visit/early withdrawal visit (up to Day 982)
Percentage of Participants With a Reduction in Use of Baseline Idiopathic Thrombocytopenic Purpura (ITP) Medication
Concomitant ITP medications included drugs such as steroids and immunosuppressive drugs. Reduction of concomitant ITP medication was defined as a reduction in dose and/or frequency of administration.
Time frame: From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)
Percentage of Participants Initiating Rescue Medication/Treatment During On-Therapy
Rescue therapy included new ITP medication, an increased dose of a concomitant ITP medication from Baseline (B/L), platelet transfusion, and splenectomy.
Time frame: From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)
| Milestone | Eltrombopag |
|---|---|
| Started | 19 |
| Completed | 15 |
| Not completed | 4 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Normal pc remained while no treatment | 1 |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medical product, whether or not related to the product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or its prolongation, results in disability/incapacity, is a congenital anomaly/birth defect, or is another event considered serious. A drug-related AE is any AE that was judged to have a relationship with the study medication by the investigator. The severity of an AE is based on the investigator's clinical judgment.
| participants | Eltrombopag |
|---|---|
| AE | 19 |
| SAE | 6 |
| Drug-Related AE | 5 |
| AE Leading to Withdrawal | 0 |
| SAE Leading to Withdrawal | 0 |
| Ongoing AE at the End of Study/Withdrawal | 15 |
| Mild AE | 6 |
| Moderate AE | 13 |
| Severe AE | 0 |
Platelet counts were measured by blood draw.
| percentage of participants | Eltrombopag |
|---|---|
| Baseline, n=19 | 5.3 |
| Week 1, n=19 | 21.1 |
| Week 2, n=19 | 63.2 |
| Week 3, n=19 | 78.9 |
| Week 4, n=19 | 73.7 |
| Week 8, n=19 | 73.7 |
| Week 12, n=16 | 68.8 |
| Week 16, n=17 | 76.5 |
| Week 20, n=15 | 73.3 |
| Week 24, n=17 | 82.4 |
| Week 28, n=16 | 81.3 |
| Week 32, n=16 | 68.8 |
| Week 36, n=18 | 66.7 |
| Week 40, n=17 | 47.1 |
| Week 44, n=17 | 58.8 |
| Week 48, n=18 | 83.3 |
| Week 52, n=16 | 62.5 |
| Week 56, n=14 | 57.1 |
| Week 60, n=16 | 50.0 |
| Week 64, n=14 | 57.1 |
| Week 68, n=14 | 57.1 |
| Week 72, n=12 | 50.0 |
| Week 76, n=12 | 75.0 |
| Week 80, n=12 | 66.7 |
| Week 84, n=13 | 69.2 |
| Week 88, n=12 | 75.0 |
| Week 92, n=11 | 72.7 |
| Week 96, n=11 | 54.5 |
| Week 100, n=13 | 46.2 |
| Week 104, n=11 | 45.5 |
| Week 108, n=11 | 72.7 |
| Week 112, n=7 | 57.1 |
| Week 116, n=7 | 85.7 |
| Week 120, n=5 | 40.0 |
| Week 124, n=6 | 16.7 |
| Week 128, n=4 | 25.0 |
| Week 132, n=2 | 50.0 |
| Week 136, n=1 | 100 |
| Last Visit/Early Withdrawal Visit, n=19 | 57.9 |
Platelet counts were measured by blood draw.
| Gi/L | Eltrombopag |
|---|---|
| Baseline, n=19 | 20.0 (3 to 117) |
| Week 1, n=19 | 36.0 (4 to 308) |
| Week 2, n=19 | 84.0 (14 to 463) |
| Week 3, n=19 | 85.0 (10 to 194) |
| Week 4, n=19 | 97.0 (5 to 259) |
| Week 8, n=19 | 102.0 (5 to 224) |
| Week 12, n=16 | 85.0 (23 to 238) |
| Week 16, n=17 | 76.0 (8 to 217) |
| Week 20, n=15 | 61.0 (7 to 252) |
| Week 24, n=17 | 70.0 (5 to 255) |
| Week 28, n=16 | 97.0 (17 to 202) |
| Week 32, n=16 | 75.0 (9 to 184) |
| Week 36, n=18 | 73.5 (3 to 233) |
| Week 40, n=17 | 45.0 (4 to 222) |
| Week 44, n=17 | 59.0 (3 to 226) |
| Week 48, n=18 | 71.5 (3 to 224) |
| Week 52, n=16 | 81.0 (5 to 303) |
| Week 56, n=14 | 58.0 (19 to 223) |
| Week 60, n=16 | 48.5 (4 to 252) |
| Week 64, n=14 | 57.5 (5 to 201) |
| Week 68, n=14 | 53.5 (3 to 200) |
| Week 72, n=12 | 51.5 (20 to 188) |
| Week 76, n=12 | 90.0 (39 to 241) |
| Week 80, n=12 | 67.5 (7 to 277) |
| Week 84, n=13 | 86.0 (20 to 280) |
| Week 88, n=12 | 65.0 (14 to 205) |
| Week 92, n=11 | 78.0 (22 to 194) |
| Week 96, n=11 | 57.0 (11 to 236) |
| Week 100, n=13 | 45.0 (15 to 282) |
| Week 104, n=11 | 44.0 (8 to 241) |
| Week 108, n=11 | 69.0 (2 to 318) |
| Week 112, n=7 | 56.0 (15 to 146) |
| Week 116, n=7 | 84.0 (38 to 148) |
| Week 120, n=5 | 21.0 (11 to 294) |
| Week 124, n=6 | 32.0 (8 to 156) |
| Week 128, n=4 | 37.0 (7 to 178) |
| Week 132, n=2 | 34.0 (18 to 50) |
| Week 136, n=1 | 51.0 (51 to 51) |
| Last Visit/Early Withdrawal Visit, n=19 | 75.0 (7 to 314) |
Maximum continuous week (MCW) is measured as the longest period (weeks) for which a participant continuously maintained platelet counts greater than or equal to 50 Gi/L and greater than or equal to twice the Baseline count.
| percentage of participants | Eltrombopag |
|---|---|
| Study Med. =<52 weeks (WKS), MCW=0 week (WK), n=2 | 0 |
| Study Med. =<52 WKS, MCW >=1 WK, n=2 | 100 |
| Study Med. =<52 WKS, MCW >=4 WKS, n=2 | 100 |
| Study Med. =<52 WKS, MCW >=7 WKS, n=2 | 50.0 |
| Study Med. =<52 WKS, MCW >=10 WKS, n=2 | 50.0 |
| Study Med. =<52 WKS, MCW >=13 WKS, n=2 | 50.0 |
| Study Med. =<52 WKS, MCW >=16 WKS, n=2 | 50.0 |
| Study Med. =<52 WKS, MCW >=19 WKS, n=2 | 50.0 |
| Study Med. =<52 WKS, MCW >=22 WKS, n=2 | 50.0 |
| Study Med. =<52 WKS, MCW >=25 WKS, n=2 | 50.0 |
| Study Med. =<52 WKS, MCW >=28 WKS, n=2 | 50.0 |
| Study Med. =<52 WKS, MCW >=31 WKS, n=2 | 50.0 |
| Study Med. =<52 WKS, MCW >=34 WKS, n=2 | 50.0 |
| Study Med. =<52 WKS, MCW >=37 WKS, n=2 | 0 |
| Study Med. =<52 WKS, MCW >=40 WKS, n=2 | 0 |
| Study Med. =<52 WKS, MCW >=43 WKS, n=2 | 0 |
| Study Med. >52 to =<78 WKS, MCW=0 WK, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=1 WK, n=1 | 100 |
| Study Med. >52 to =<78 WKS, MCW >=4 WKS, n=1 | 100 |
| Study Med. >52 to =<78 WKS, MCW >=7 WKS, n=1 | 100 |
| Study Med. >52 to =<78 WKS, MCW >=10 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=13 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=16 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=19 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=22 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=25 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=28 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=31 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=34 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=37 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=40 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=43 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=52 WKS, n=1 | 0 |
| Study Med. >52 to =<78 WKS, MCW >=65 WKS, n=1 | 0 |
| Study Med. >78 to =<104 WKS, MCW=0 WK, n=1 | 0 |
| Study Med. >78 to =<104 WKS, MCW >=1 WK, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=4 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=7 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=10 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=13 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=16 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=19 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=22 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=25 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=28 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=31 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=34 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=37 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=40 WKS, n=1 | 100 |
| Study Med. >78 to =<104 WKS, MCW >=43 WKS, n=1 | 0 |
| Study Med. >78 to =<104 WKS, MCW >=52 WKS, n=1 | 0 |
| Study Med. >78 to =<104 WKS, MCW >=65 WKS, n=1 | 0 |
| Study Med. >78 to =<104 WKS, MCW >=78 WKS, n=1 | 0 |
| Study Med. >104 to =<130 WKS, MCW=0 WK, n=11 | 0 |
| Study Med. >104 to =<130 WKS, MCW >=1 WK, n=11 | 100 |
| Study Med. >104 to =<130 WKS, MCW >=4 WKS, n=11 | 90.9 |
| Study Med. >104 to =<130 WKS, MCW >=7 WKS, n=11 | 90.9 |
| Study Med. >104 to =<130 WKS, MCW >=10 WKS, n=11 | 90.9 |
| Study Med. >104 to =<130 WKS, MCW >=13 WKS, n=11 | 90.9 |
| Study Med. >104 to =<130 WKS, MCW >=16 WKS, n=11 | 81.8 |
| Study Med. >104 to =<130 WKS, MCW >=19 WKS, n=11 | 63.6 |
| Study Med. >104 to =<130 WKS, MCW >=22 WKS, n=11 | 54.5 |
| Study Med. >104 to =<130 WKS, MCW >=25 WKS, n=11 | 45.5 |
| Study Med. >104 to =<130 WKS, MCW >=28 WKS, n=11 | 45.5 |
| Study Med. >104 to =<130 WKS, MCW >=31 WKS, n=11 | 36.4 |
| Study Med. >104 to =<130 WKS, MCW >=34 WKS, n=11 | 36.4 |
| Study Med. >104 to =<130 WKS, MCW >=37 WKS, n=11 | 18.2 |
| Study Med. >104 to =<130 WKS, MCW >=40 WKS, n=11 | 18.2 |
| Study Med. >104 to =<130 WKS, MCW >=43 WKS, n=11 | 18.2 |
| Study Med. >104 to =<130 WKS, MCW >=52 WKS, n=11 | 18.2 |
| Study Med. >104 to =<130 WKS, MCW >=65 WKS, n=11 | 9.1 |
| Study Med. >104 to =<130 WKS, MCW >=78 WKS, n=11 | 9.1 |
| Study Med. >104 to =<130 WKS, MCW >=91 WKS, n=11 | 9.1 |
| Study Med. >104 to =<130 WKS, MCW >=104 WKS, n=11 | 0 |
| Study Med. >104 to =<130 WKS, MCW >=117 WKS, n=6 | 0 |
| Study Med. >130 WKS, MCW=0 WK, n=4 | 0 |
| Study Med. >130 WKS, MCW >=1 WK, n=4 | 100 |
| Study Med. >130 WKS, MCW >=4 WKS, n=4 | 50.0 |
| Study Med. >130 WKS, MCW >=7 WKS, n=4 | 50.0 |
| Study Med. >130 WKS, MCW >=10 WKS, n=4 | 50.0 |
| Study Med. >130 WKS, MCW >=13 WKS, n=4 | 25.0 |
| Study Med. >130 WKS, MCW >=16 WKS, n=4 | 25.0 |
| Study Med. >130 WKS, MCW >=19 WKS, n=4 | 25.0 |
| Study Med. >130 WKS, MCW >=22 WKS, n=4 | 25.0 |
| Study Med. >130 WKS, MCW >=25 WKS, n=4 | 25.0 |
| Study Med. >130 WKS, MCW >=28 WKS, n=4 | 25.0 |
| Study Med. >130 WKS, MCW >=31 WKS, n=4 | 25.0 |
| Study Med. >130 WKS, MCW >=34 WKS, n=4 | 25.0 |
| Study Med. >130 WKS, MCW >=37 WKS, n=4 | 25.0 |
| Study Med. >130 WKS, MCW >=40 WKS, n=4 | 25.0 |
| Study Med. >130 WKS, MCW >=43 WKS, n=4 | 0 |
| Study Med. >130 WKS, MCW >=52 WKS, n=4 | 0 |
| Study Med. >130 WKS, MCW >=65 WKS, n=4 | 0 |
| Study Med. >130 WKS, MCW >=78 WKS, n=4 | 0 |
| Study Med. >130 WKS, MCW >=91 WKS, n=4 | 0 |
| Study Med. >130 WKS, MCW >=104 WKS, n=4 | 0 |
| Study Med. >130 WKS, MCW >=117 WKS, n=4 | 0 |
| Total, MCW=0 WK, n=19 | 0 |
| Total, MCW >=1 WK, n=19 | 100 |
| Total, MCW >=4 WKS, n=19 | 84.2 |
| Total, MCW >=7 WKS, n=19 | 78.9 |
| Total, MCW >=10 WKS, n=19 | 73.7 |
| Total, MCW >=13 WKS, n=19 | 68.4 |
| Total, MCW >=16 WKS, n=19 | 63.2 |
| Total, MCW >=19 WKS, n=19 | 52.6 |
| Total, MCW >=22 WKS, n=19 | 47.4 |
| Total, MCW >=25 WKS, n=19 | 42.1 |
| Total, MCW >=28 WKS, n=19 | 42.1 |
| Total, MCW >=31 WKS, n=19 | 36.8 |
| Total, MCW >=34 WKS, n=19 | 36.8 |
| Total, MCW >=37 WKS, n=19 | 21.1 |
| Total, MCW >=40 WKS, n=19 | 21.1 |
| Total, MCW >=43 WKS, n=19 | 10.5 |
| Total, MCW >=52 WKS, n=17 | 11.8 |
| Total, MCW >=65 WKS, n=17 | 5.9 |
| Total, MCW >=78 WKS, n=16 | 6.3 |
| Total, MCW >=91 WKS, n=15 | 6.7 |
| Total, MCW >=104 WKS, n=15 | 0 |
| Total, MCW >=117 WKS, n=10 | 0 |
Maximum continuous week is measured as the longest period (weeks) for which a participant continuously maintained platelet counts greater than or equal to 50 Gi/L and greater than or equal to twice the Baseline count.
| weeks | Eltrombopag |
|---|---|
| Total, n=19 | 19.0 (1 to 91) |
| 3 Months (13 Weeks), n=18 | 5.0 (0 to 11) |
| 6 Months (26 Weeks), n=19 | 10.0 (0 to 24) |
| 9 Months (39 Weeks), n=19 | 12.0 (0 to 36) |
| 12 Months (52 Weeks), n=17 | 14.0 (0 to 36) |
| 15 Months (65 Weeks), n=17 | 14.0 (0 to 40) |
| 18 Months (78 Weeks), n=16 | 15.0 (0 to 53) |
| 21 Months (91 Weeks), n=15 | 14.0 (0 to 64) |
| 24 Months (104 Weeks), n=15 | 19.0 (0 to 76) |
| 27 Months (117 Weeks), n=10 | 17.5 (0 to 91) |
| 30 Months (130 Weeks), n=4 | 7.5 (3 to 40) |
Any bleeding(s) with an onset on or after the start date of study medication was recorded as a bleeding episode(s).
| percentage of participants | Eltrombopag |
|---|---|
| Baseline, n=19 | 63 |
| Week 1, n=19 | 32 |
| Week 2, n=19 | 21 |
| Week 3, n=19 | 16 |
| Week 4, n=19 | 5 |
| Week 8, n=19 | 11 |
| Week 12, n=16 | 13 |
| Week 16, n=17 | 12 |
| Week 20, n=15 | 40 |
| Week 24, n=17 | 6 |
| Week 28, n=16 | 25 |
| Week 32, n=16 | 19 |
| Week 36, n=18 | 39 |
| Week 40, n=17 | 35 |
| Week 44, n=17 | 24 |
| Week 48, n=18 | 22 |
| Week 52, n=16 | 31 |
| Week 56, n=14 | 29 |
| Week 60, n=16 | 13 |
| Week 64, n=14 | 21 |
| Week 68, n=14 | 29 |
| Week 72, n=12 | 8 |
| Week 76, n=12 | 8 |
| Week 80, n=12 | 25 |
| Week 84, n=13 | 0 |
| Week 88, n=12 | 8 |
| Week 92, n=11 | 9 |
| Week 96, n=11 | 9 |
| Week 100, n=13 | 8 |
| Week 104, n=11 | 27 |
| Week 108, n=11 | 27 |
| Week 112, n=7 | 14 |
| Week 116, n=7 | 0 |
| Week 120, n=5 | 0 |
| Week 124, n=6 | 33 |
| Week 128, n=4 | 25 |
| Week 132, n=2 | 50 |
| Week 136, n=1 | 0 |
| Last Visit/Early Withdrawal, n=19 | 21 |
Concomitant ITP medications included drugs such as steroids and immunosuppressive drugs. Reduction of concomitant ITP medication was defined as a reduction in dose and/or frequency of administration.
| percentage of participants | Eltrombopag |
|---|---|
| Percentage of Participants With a Reduction in Use of Baseline Idiopathic Thrombocytopenic Purpura (ITP) Medication | 87 |
Rescue therapy included new ITP medication, an increased dose of a concomitant ITP medication from Baseline (B/L), platelet transfusion, and splenectomy.
| percentage of participants | Eltrombopag |
|---|---|
| Any Rescue Therapy | 21 |
| New ITP Medication | 11 |
| Increase in Concomitant ITP Medication from B/L | 11 |
| Platelet Transfusion | 0 |
| Splenectomy | 0 |
Collected over Adverse events (AEs) and serious adverse events (SAEs) with an onset on or after the start date of study medication were collected until the end of the study (up to 981 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag | — | 6/19 (31.6%) | 19/19 (100%) |
| Event | Eltrombopag |
|---|---|
| CataractEye disorders | 2/19 |
| Abdominal painGastrointestinal disorders | 1/19 |
| Mallory-Weiss syndromeGastrointestinal disorders | 1/19 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 1/19 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 1/19 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 1/19 |
| Cystitis-like symptomRenal and urinary disorders | 1/19 |
| MenorrhagiaReproductive system and breast disorders | 1/19 |
| Event | Eltrombopag |
|---|---|
| NasopharyngitisInfections and infestations | 12/19 |
| HeadacheNervous system disorders | 4/19 |
| BronchitisInfections and infestations | 3/19 |
| DiarrhoeaGastrointestinal disorders | 3/19 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 3/19 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/19 |
| EczemaSkin and subcutaneous tissue disorders | 3/19 |
| InsomniaPsychiatric disorders | 3/19 |
| HypertensionVascular disorders | 3/19 |
| CystitisInfections and infestations | 2/19 |
| Age, Continuous(Years) | Eltrombopag |
|---|---|
| Mean | 54.7 ± 13.57 |
| Sex: Female, Male(Participants) | Eltrombopag |
|---|---|
| Female | 12 |
| Male | 7 |
| Race/Ethnicity, Customized(participants) | Eltrombopag |
|---|---|
| Asian - Japanese Heritage | 19 |
The record gives a start of May 2008, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag
Purpura, Thrombocytopenic, Idiopathic →